Pluri entered strategic collaborations across Asia, Europe and the United States ('U.S.”) to transform food and agriculture production via its subsidiaries’ advanced cell expansion ...

Oncopeptides AB ( ($SE:ONCO) ) has shared an update. Oncopeptides AB announced a change in the number of votes due to the conversion of class C ...

Korean biosimilar specialist Celltrion has penned a deal worth more than $740 million biobucks for two preclinical autoimmune ...

PROPOSED LISTING OF CELL C HOLDINGS LIMITED ON THE MAIN BOARD OF THE JSE LIMITED AND ABRIDGED PRE-LISTING STATEMENT THE ABRIDGED PRE-LISTING STATEMENT DOES NOT CONSTITUTE AN OFFER TO ANY PERSON IN ANY ...

Last year, researchers at the University of California, Riverside, developed a novel "molecular crowbar" strategy to degrade ...

Priority Research Communication by Professor Yogesh Dwivedi and colleagues at the University of Alabama at Birmingham reports original, peer-reviewed findings demonstrating that long noncoding RNAs ...

One of the oldest challenges in oncology is creating a drug that kills cancer cells while sparing healthy ones. Peptides are ...

Occupying part of the historic Crewe Works site, the expanded facilities opened on October 28 include three new heating, ...

Celltrion will develop and commercialize Kaigene's nonclinical-stage antibody assets, KG006 and KG002, under an exclusive licensing agreement. -- Kaigene will receive $8M upfront payment and up to ...

On November 9th, FOTON Motor held its 2026 Global Partners Conference in Beijing, themed "DRIVE TO GREAT". Over 2,000 dealers, key clients, partners, and media representatives from more than 140 ...

Kaigene Inc. has entered into an exclusive global licensing agreement with Celltrion Inc. for two of Kaigene's nonclinical-stage assets, KG006 and KG002.

Famous for surviving an extreme destruction test at the hands of Top Gear some 20 years ago, a ninth-generation example with ...